U
15.40
0.34 (2.26%)
| Previous Close | 15.06 |
| Open | 14.98 |
| Volume | 2,625,203 |
| Avg. Volume (3M) | 1,911,003 |
| Market Cap | 750,643,712 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 28.74 |
| Price / Book | 14.83 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2025 - 1 Mar 2025 |
| Operating Margin (TTM) | -1,776.91% |
| Diluted EPS (TTM) | -4.95 |
| Quarterly Revenue Growth (YOY) | 62.50% |
| Total Debt/Equity (MRQ) | 889.83% |
| Current Ratio (MRQ) | 6.51 |
| Operating Cash Flow (TTM) | -179.42 M |
| Levered Free Cash Flow (TTM) | -125.18 M |
| Return on Assets (TTM) | -16.62% |
| Return on Equity (TTM) | -147.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | uniQure N.V. | Bullish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.24% |
| % Held by Institutions | 89.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 58.00 (Cantor Fitzgerald, 276.62%) | Buy |
| Median | 28.50 (85.07%) | |
| Low | 20.00 (Mizuho, 29.87%) | Hold |
| 20.00 (Goldman Sachs, 29.87%) | Hold | |
| 20.00 (RBC Capital, 29.87%) | Buy | |
| Average | 33.88 (120.00%) | |
| Total | 6 Buy, 2 Hold | |
| Avg. Price @ Call | 15.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 19 Dec 2024 | 20.00 (29.87%) | Hold | 15.47 |
| Stifel | 16 Dec 2024 | 32.00 (107.79%) | Buy | 17.40 |
| Goldman Sachs | 12 Dec 2024 | 20.00 (29.87%) | Hold | 15.06 |
| 06 Nov 2024 | 9.00 (-41.56%) | Hold | 7.16 | |
| Leerink Partners | 11 Dec 2024 | 44.00 (185.71%) | Buy | 15.65 |
| RBC Capital | 11 Dec 2024 | 20.00 (29.87%) | Buy | 15.65 |
| 06 Nov 2024 | 14.00 (-9.09%) | Buy | 7.16 | |
| Cantor Fitzgerald | 10 Dec 2024 | 58.00 (276.62%) | Buy | 15.30 |
| 06 Nov 2024 | 28.00 (81.82%) | Buy | 7.16 | |
| HC Wainwright & Co. | 10 Dec 2024 | 25.00 (62.34%) | Buy | 15.30 |
| 06 Nov 2024 | 25.00 (62.34%) | Buy | 7.16 | |
| Raymond James | 10 Dec 2024 | 52.00 (237.66%) | Buy | 15.30 |
| 10 Oct 2024 | 20.00 (29.87%) | Buy | 5.42 | |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Dec 2024 | Announcement | uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease |
| 21 Nov 2024 | Announcement | uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy |
| 05 Nov 2024 | Announcement | uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress |
| 15 Oct 2024 | Announcement | uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS |
| 23 Sep 2024 | Announcement | uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |